<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02974933</url>
  </required_header>
  <id_info>
    <org_study_id>HubeiCH</org_study_id>
    <nct_id>NCT02974933</nct_id>
  </id_info>
  <brief_title>Apatinib Mesylate Combined With Pemetrexed in the Treatment of Pretreated Advanced Non-squamous Non-small Cell Lung Cancer</brief_title>
  <official_title>Apatinib Mesylate Combined With Pemetrexed in the Treatment of Pretreated Advanced Non-squamous Non-small Cell Lung Cancer ：Single Arm Exploratory Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wuling Ou</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hubei Clinical Research Collaboration Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hubei Cancer Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy of apatinib mesylate combined with
      pemetrexed alone in advanced non-small cell lung cancer patients in the second or second line
      of treatment of progression-free survival
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is a one-arm study. The progression-free survival will be evaluated.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 2016</start_date>
  <completion_date type="Anticipated">November 2018</completion_date>
  <primary_completion_date type="Anticipated">November 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progression free survival</measure>
    <time_frame>4 weeks</time_frame>
    <description>evaluation per 28 days</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>4 weeks</time_frame>
    <description>evaluation per 28 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>disease control rate</measure>
    <time_frame>4 weeks</time_frame>
    <description>evaluation per 28 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>objective response rate</measure>
    <time_frame>4 weeks</time_frame>
    <description>evaluation per 28 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Event</measure>
    <time_frame>4 weeks</time_frame>
    <description>evaluation per 28 days</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Nonsmall Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>apatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>combined with pemetrexed</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apatinib combined with pemetrexed</intervention_name>
    <description>For those pretreated non-squamous non-small cell lung cancer, treat with apatinib 500mg Qd, po.combined with pemetrexed continue until disease progression</description>
    <arm_group_label>apatinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Aged from 18 years to 70years.

          2. Histologically or cytologically confirmed non-squamous non-small cell lung
             cancer(stage IIIB/IV).

          3. Measurable lesions as defined by RECIST criteria.

          4. Locally advanced lung cancer cannot treat with surgery, recurrent or metastatic lung
             cancer

          5. ECOG performance status (PS) of 0 to 1.

          6. Life expectancy ≥3 months.

          7. Informed consent.

        Exclusion Criteria:

          1. Squamous carcinoma (including adeno-squamous carcinoma), small cell lung cancer.

          2. Newly diagnosed Central Nervous System (CNS) metastases that have not yet been
             definitively treated with surgery and/or radiation.

          3. Tumor invade big vessels or close to big vessels (less than 5mm)

          4. Obvious cavity or necrosis formed in the tumor

          5. Uncontrolled hypertension

          6. Myocardial ischemia or infarction more than stage II, cardiac insufficiency.

          7. Abnormal coagulation (INR&gt;1.5 or PT&gt;ULN+4, or APTT&gt;1.5 ULN), bleeding tendency or
             receiving coagulation therapy

          8. The active HBV or HCV infection

          9. History of other malignancies except cured basal cell carcinoma of skin and carcinoma
             in-situ of uterine cervix.

         10. Hemoptysis, more than 2.5ml daily

         11. Thrombosis in 12 months, including pulmonary thrombosis, stoke, or deep venous
             thrombosis.

         12. Unhealed bone fracture or wound for long time

         13. Received big surgery, had bone fracture or ulcer in 4 weeks.

         14. Urine protein≥++, or urine protein in 24 hours≥1.0g

         15. Use of CYP3A4 inhibitor within 7 days or CYP3A4 inducer within 12 days prior to
             enrollment

         16. Have received prior treatment with VEGFR TKI (Bevacizumab is permitted).

         17. Pregnant or lactating woman, or woman unwilling to practice contraception during the
             study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ou Wu Ling, MD</last_name>
    <email>609700817@qq.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ou wuling</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430079</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ou Wu ling, 40</last_name>
      <phone>13469989766</phone>
      <phone_ext>86</phone_ext>
      <email>609700817@qq.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 21, 2016</study_first_submitted>
  <study_first_submitted_qc>November 23, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 29, 2016</study_first_posted>
  <last_update_submitted>February 15, 2017</last_update_submitted>
  <last_update_submitted_qc>February 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hubei Cancer Hospital</investigator_affiliation>
    <investigator_full_name>Wuling Ou</investigator_full_name>
    <investigator_title>Deputy Chief Physician</investigator_title>
  </responsible_party>
  <keyword>apatinib</keyword>
  <keyword>pemetrexed</keyword>
  <keyword>NSCLC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

